JP2014515477A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515477A5
JP2014515477A5 JP2014511615A JP2014511615A JP2014515477A5 JP 2014515477 A5 JP2014515477 A5 JP 2014515477A5 JP 2014511615 A JP2014511615 A JP 2014511615A JP 2014511615 A JP2014511615 A JP 2014511615A JP 2014515477 A5 JP2014515477 A5 JP 2014515477A5
Authority
JP
Japan
Prior art keywords
protein
her2
subject
cutoff
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515477A (ja
JP6468838B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/038867 external-priority patent/WO2012159115A1/en
Publication of JP2014515477A publication Critical patent/JP2014515477A/ja
Publication of JP2014515477A5 publication Critical patent/JP2014515477A5/ja
Application granted granted Critical
Publication of JP6468838B2 publication Critical patent/JP6468838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014511615A 2011-05-19 2012-05-21 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 Active JP6468838B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488028P 2011-05-19 2011-05-19
US61/488,028 2011-05-19
PCT/US2012/038867 WO2012159115A1 (en) 2011-05-19 2012-05-21 Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017093074A Division JP6626037B2 (ja) 2011-05-19 2017-05-09 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法

Publications (3)

Publication Number Publication Date
JP2014515477A JP2014515477A (ja) 2014-06-30
JP2014515477A5 true JP2014515477A5 (cg-RX-API-DMAC7.html) 2015-05-14
JP6468838B2 JP6468838B2 (ja) 2019-02-13

Family

ID=47175183

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014511615A Active JP6468838B2 (ja) 2011-05-19 2012-05-21 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
JP2017093074A Active JP6626037B2 (ja) 2011-05-19 2017-05-09 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017093074A Active JP6626037B2 (ja) 2011-05-19 2017-05-09 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法

Country Status (7)

Country Link
US (2) US20120295259A1 (cg-RX-API-DMAC7.html)
EP (2) EP3124975B1 (cg-RX-API-DMAC7.html)
JP (2) JP6468838B2 (cg-RX-API-DMAC7.html)
CA (1) CA2835284C (cg-RX-API-DMAC7.html)
ES (2) ES2615265T3 (cg-RX-API-DMAC7.html)
SG (1) SG194609A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012159115A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20120295259A1 (en) 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US10451614B2 (en) 2016-03-15 2019-10-22 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
US4997928A (en) 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
US5654442A (en) 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE146508T1 (de) 1990-11-02 1997-01-15 Zeneca Ltd Polysubstituierte phthalocyanine
JP2758730B2 (ja) 1991-04-25 1998-05-28 三菱電機株式会社 放電励起パルスレーザ発振装置
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1993021230A1 (en) 1992-04-10 1993-10-28 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
JP3464798B2 (ja) 1992-07-31 2003-11-10 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 光活性化化学発光基質
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US20030235832A1 (en) 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US6191278B1 (en) 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
EP1305632B1 (en) 2000-05-04 2011-07-27 Siemens Healthcare Diagnostics Products GmbH Methods for detection of multiple analytes
WO2003051669A1 (en) 2001-12-18 2003-06-26 Aclara Biosciences, Inc. Photoactivation device and method
EP1478765A4 (en) 2002-03-05 2006-12-06 Aclara Biosciences Inc MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
ATE442589T1 (de) 2002-07-25 2009-09-15 Aclara Biosciences Inc Nachweis der rezeptoroligomerisierung
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
WO2005037071A2 (en) 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2438442B1 (en) * 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20120295259A1 (en) 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US20100233732A1 (en) 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) * 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
ES2363669B1 (es) * 2009-06-10 2012-08-09 Fundacio Privada Institut D'investigacio Biomedica De Bellvitge (Idibell) Metodo para determinar el riesgo de desarrollar metastasis cerebral y un kit para llevar a cabo dicho procedimiento
JP5795311B2 (ja) * 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択

Similar Documents

Publication Publication Date Title
Hermine et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
US9945870B2 (en) Methods for determining responsiveness to an anti-CD47 agent
Mendell et al. Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in patients with advanced non-small cell lung cancer
Samuel et al. Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers
Gruel et al. Biological dosimetry by automated dicentric scoring in a simulated emergency
JP2023529026A5 (cg-RX-API-DMAC7.html)
JP2018502828A5 (cg-RX-API-DMAC7.html)
Singarayer et al. A systematic review and meta-analysis of the diagnostic performance of BRAF V600E immunohistochemistry in thyroid histopathology
Polivka Jr et al. Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?
Dreyling et al. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
Zhao et al. CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis
JP2011515497A5 (cg-RX-API-DMAC7.html)
JP2016536330A5 (cg-RX-API-DMAC7.html)
KR102067327B1 (ko) 최적의 암 치료를 위한 Her2 단백질 정량
JP2015530868A5 (cg-RX-API-DMAC7.html)
WO2018075869A1 (en) Method of predicting graft versus host disease
JP2018508532A5 (cg-RX-API-DMAC7.html)
Massard et al. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study
JP2018532978A (ja) 最適な癌療法のためのFR−αおよびGARTタンパク質の定量
JP2014524571A (ja) がん治療用予測因子
WO2018150031A1 (en) Method of detecting cancer or cancer cells
Khadela et al. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
CN113174439B (zh) 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用
Zhong et al. Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy
JP2020524794A (ja) 最適な癌療法のためのslfn11タンパク質の定量